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Age-related macular degeneration (AMD) is an ocular inflammatory diseases treated mainly by means 
of a bevacizumab (Avastin®) or ranibizumab (Lucentis®) intravitreal injection. Among these drugs, 
only ranibizumab has a specific therapeutic indication for AMD. Considering that, the off-label use on 
ophthalmic therapy seems to become a rule when it should be an exception. Furthermore, bevacizumab 
presentation consists of multi-dose vials although it does not contain preservatives in its formula. The 
current literature review aimed at assessing the risks for the patient related to the use of off-label indication 
and multi-dose vials on AMD treatment. Considering this, the proposal related to the Brazilian Public 
Consultation no.10, dated September 12, 2012, which proposes the Clinical Protocol and Therapeutic 
Guidelines for AMD treatment, was evaluated. This systematic review allowed to conclude that the 
bevacizumab off-label indication results in increased risks for the patient when compared to the 
product with specific therapeutic indication for AMD treatment (ranibizumab), especially referring to 
the significant raise in the adverse events. The risks for the patient related to the multi-dose vial use, 
referring to the microbiological stability and dose precision, were also made clear.
Uniterms: Age-related macular degeneration/treatment. Ranibizumab/intravitreal injection. Bevacizumab/
intravitreal injection. Ophthalmic therapy/off-label use. Off-label indication/patients risks. Multi-dose 
vials/patients risks.
A degeneração macular relacionada à idade (DMRI) é uma doença ocular inflamatória tratada 
principalmente por injeção intravítrea de bevacizumabe (Avastin®) ou de ranibizumabe (Lucentis®). 
Entre os medicamentos citados, apenas o ranibizumabe tem indicação terapêutica específica para uso 
oftálmico. Considerando essa realidade, o uso off-label na terapia oftálmica parece constituir regra quando 
deveria ser exceção. Ademais, a apresentação do bevacizumabe consiste em frascos de múltipla-dose, 
embora esse medicamento não contenha conservante em sua fórmula. A presente revisão da literatura 
avaliou os riscos ao paciente relativos ao uso indicado off-label e de frascos de múltipla-dose no 
tratamento de DMRI. Nesse sentido, avaliou-se a proposta relativa à Consulta Pública Brasileira nº 10, 
de 12 de setembro de 2012, que propõe o Protocolo Clínico e Diretrizes Terapêuticas para o tratamento 
de DMRI. O levantamento sistemático de trabalhos científicos e de informações relevantes de banco de 
dados eletrônicos permitiu concluir que a indicação off-label do bevacizumabe acarreta riscos maiores 
ao paciente, quando comparado ao produto com indicação terapêutica específica para o tratamento de 
DMRI (ranibizumabe), especialmente quanto ao aumento significativo de eventos adversos. Evidenciaram-
se, também, os riscos ao paciente relativos ao uso de frascos de múltipla-dose, quanto à estabilidade 
microbiológica e à precisão da dose.
Unitermos: Degeneração macular /tratamento. Ranibizumabe/injeção intravítrea. Bevacizumabe/injeção 
intravítrea. Terapia oftálmica/uso off-label. Indicação off-label/riscos ao paciente. Frascos de multi-dose/
riscos ao paciente.
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INTRODUCTION
The recombinant monoclonal antibodies (mAb) 
used in ophthalmic therapy consist of immunoglobulin 
produced from B cell clones which recognize specific 
antigens. Problems related to the rejection of said 
antibodies by the organism were circumvented by the 
adoption of humanized or completely human chimeric 
monoclonal antibodies. Chimeric monoclonal antibodies 
consist of human origin amino acid sequences, with 
murine origin sequences in the regions that bind to the 
antigenic determinants. A significant part of the amino acid 
sequences has a human origin in humanized antibodies, 
with a portion of less than 5% corresponding to murine 
origin. Human antibodies have 100% human origin 
sequences. Murine antibodies, or mouse antibodies, 
are identified by the immune system as foreign agents, 
inducing the organism to produce HAMA (human anti-
mouse antibody). Thus, the organism quickly eliminates 
those antibodies and immune complexes, thus causing 
kidney injuries. Therefore, the therapeutic efficacy and 
the drug safety should be assessed by close clinical tests 
(Santos et al., 2006).
The main therapeutic use of monoclonal antibodies in 
ophthalmology refers to the treatment of inflammatory eye 
diseases, especially in cases of severe and refractory uveitis 
(Infliximab, Remicade®, Janssen-Cilag; adalimumab, 
Humira®, Abbott), diabetic retinopathy (DR) and age-
related macular degeneration (AMD) (bevacizumab, 
Avastin®, Genentech; ranibizumab, Lucentis®, Novartis) 
(Gragoudas et al., 2004; Santos et al., 2006; Rosenfeld et 
al., 2005, 2006; Rich et al., 2006). However, the authorized 
therapeutic indication for both drugs (infliximab and 
adalimumab) only includes treatments for rheumatoid 
arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s 
disease, psoriasis, and polyarticular juvenile idiopathic 
arthritis (Maini et al., 1999; Weinblat et al., 2003). 
Adalimumab shows a significant advantage when compared 
to infliximab (chimeric antibody) due to the totally 
humanized origin of this antibody (Wiens et al., 2010). For 
bevacizumab, the authorized therapeutic indication regards 
the treatment of neoplasms, such as metastatic colorectal 
cancer, lung cancer, breast cancer, metastatic renal cell 
cancer, among others (Ellis, 2006; Sandler et al., 2006; 
Santos et al., 2006; Miller et al., 2007; Roche, 2011). Thus, 
the off-label use of monoclonal antibodies in ophthalmic 
therapy seems to be a rule. Among these drugs, the only 
exception is ranibizumab, which shows specific therapeutic 
indication for AMD treatment.
The rationale provided by ophthalmologists for 
the non-authorized use of monoclonal antibodies in the 
treatment of severe and refractory uveitis has been based 
on its limited clinical success and on the partial failure of 
steroids and immunosuppressive drugs in eye inflammation 
control, as well as the increased rate of adverse events 
caused by steroid agents (Regatieri et al., 2010).
For neovascular diseases, the vascular endothelial 
growth factor (VEGF) actively participates in the formation 
of new vessels in several neovascular conditions, including 
diabetic retinopathy (DR) and AMD. The abnormal growth 
of blood vessels around the retina may cause sight loss 
(Regatieri et al., 2010). As an intravitreal injection, the 
anti-VEGF monoclonal antibody [bevacizumab (Avastin®, 
Genentech)] and the VEGF fragment [ranibizumab 
(Lucentis®, Novartis)] showed significant regression of 
choroidal and retinal neovascularization in experimental 
studies (Campochiaro, 2004). The apparent similarity in 
the therapeutic efficacy of these antibodies has justified 
the off-label use of bevacizumab by ophthalmologists.
This work aimed at reviewing the literature related 
to the off-label indication and the risks associated with the 
use of multi-dose vials in age-related macular degeneration 
treatment. For this purpose, a systematic survey of scientific 
works and of electronic database relevant information up to 
November 2012 was carried out. 
Off-label indications and drug promotional 
practices
In Brazil, the registration of new drugs is granted 
after the confirmation of their quality, safety, and efficacy, 
and the last two characteristics should be supported by 
clinical trials. However, other indications, different from 
those for which the drug was granted the registration, 
may be proposed, at the prescribing physician’s discretion 
and risk: this is off-label drug use. A typical example of 
a non-approved indication is the case of treatment in rare 
diseases. In these cases, it is not possible to perform a 
clinical trial to propose an indication; therefore, off-label 
drug use may be tolerated during an indefinite period of 
time (ANVISA, 2005).
The term “different situation” refers to non-
approved indications for which, after the assessment 
period, the industry proposes a registration change, such 
as, for example, requesting the extension of drug use for 
another age group or use for a different phase of the same 
disease for which the indication was approved, or even 
an extension of its indication for another disease. The 
latter can be exemplified with the case of bevacizumab. 
This drug, which was at first approved for treatment of 
metastatic colorectal cancer in 2004, had its registration 
changed in 2006 and in 2008. These changes regard the 
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extension of therapeutic indications for lung and breast 
cancer treatment, approved by ANVISA.
On the other hand, the indication of a certain 
drug may be restricted when compared to the originally 
approved one. In this case, pharmacovigilance determines 
the damage caused by these marketed products, identifying 
the risk and interfering in a timely manner in the drug 
registration (ANVISA, 2012).
For the approval of a new therapeutic indication, 
the submission of the periodic safety reports and the risk 
minimization plan is mandatory, according to IN No. 
14, which approved the Pharmacovigilance Guides for 
the performance of RDC No. 4, dated 2009. This safety 
assurance may be circumvented in case of off-label 
indication use, causing risks for patients.
The off-label indication may help fixing the gap 
between the time in which the research shows efficacy 
of a certain drug and formal approval by the regulatory 
agency. However, there’s a thin line between the supply 
of information related to the off-label use of a product 
and its promotion for said usage. This practice may bring 
beneficial results, indicating new ways for scientific 
research on the standardization of indications and dosages. 
On the other hand, in addition to lack of therapeutic effect, 
it can also result in adverse reactions (Di Paolo et al., 2006; 
Naubert et al., 2004).
The more an off-label indication use is spread, 
the higher the possibility of the industry using this way 
to circumvent the applicable regulation - which has 
the objective of ensuring drug efficacy and safety. In 
the United States, one out of five prescriptions regards 
treatment for an illness for which the drug was not 
approved (Radley et al., 2006). This study revealed that 
most off-label uses happen without scientific support. It 
is estimated that 23% to 60% of these medications are 
responsible for adverse reactions in children (Naubert et 
al., 2004; Patel et al., 2007).
Recent cases justify the results related to the 
increased incidence of prescriptions without scientific 
support. In 2012, several frauds involving big and well-
known pharmaceutical industries were discovered. 
Among them, Abbott and GlaxoSmithKline (GSK) stand 
out. According to a report from the FDA (Food and Drug 
Administration) Office of Criminal Investigations, Abbott 
agreed to pay US$ 1.6 billion in compensation for an 
advertisement considered to be deceiving in the United 
States. The company instructed its marketing departments 
on the creation of campaigns for the drug Depakote® for 
uses that had not been approved by the FDA. According 
to a report from the United States Department of Justice, 
Abbott created a specific department for marketing the 
drug in hospitals. Depakote® is indicated in cases of bipolar 
disorder and epilepsy; however, it was being sold for the 
treatment of dementia and autism (off-label indication). 
Legal documents also revealed that Abbott marketed the 
drug for the treatment of schizophrenia, although clinical 
tests failed to prove that it had greater efficacy when 
compared to antipsychotic drugs traditionally used in the 
treatment of this disease.
In an article published on The New York Times, 
another huge pharmaceutical industry, GlaxoSmithKline 
(GSK), stated that it will pay the amount of US$ 3 
billion in the USA in order to close a case of illegal drug 
advertisement and adoption of deceiving prices. This 
decision may put an end to what is considered to be the 
biggest Public Health fraud in the history of the country 
by United States government employees. The breaches 
indicated by the United States Department of Justice 
include: advertisements for the antidepressant Paxil® 
targeted patients under 18 years old, as the medication 
had the approval for adult use only; Wellbutrin®, another 
antidepressant used to treat smoking, was marketed for 
uses not approved by the FDA, such as weight loss and 
treatment of sexual dysfunctions; in addition to claims that 
the company did not offer the government its best prices on 
the Medicare drug purchase program (The United States 
public health system). The drug promotion also involved 
the distribution of potentially deceiving articles published 
in medical magazines.
In April 2012, the United States pharmaceutical 
industry Merck, Sharp & Dohme was convicted by the 
Boston District Court to pay a fine at the amount of 
approximately 322 million dollars due to Vioxx promotion. 
As per the legal decision, once approved, the drug cannot 
be marketed or promoted for so-called off-label use - any 
non-specified and non-approved use. In May 1999, the 
FDA approved the use of Vioxx for three indications, 
but did not approve its use for rheumatoid arthritis until 
April 2002. In the meantime, Merck promoted Vioxx for 
rheumatoid arthritis for almost three years. This promotion 
resulted in a warning letter from the FDA, issued in 
September 2001. In 2004, the product was withdrawn 
from market for causing risk of severe cardiovascular 
events in patients.
In light of the above, off-label drug use requires 
rigorous inspection by the regulatory agencies. Therefore, 
the proposal of replacing a drug indicated for AMD 
(neovascular form) treatment with another one with off-
label use, as provided for in ANVISA Public Consultation 
No. 10, dated September 12, 2012, may be considered to 
be at least a precedent for future cases and an incentive 
for the promotional practice of drug use for a non-
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approved indication. This issue presents itself with greater 
importance after a statement regarding the illegality and 
unconstitutionality of RDC No. 96/08, which regulates 
advertisement, publicity, information, and other practices 
aimed at divulgation or commercial promotion of drugs. 
Said position, which was restated on October 22, 2009, 
by the Supreme Federal Court, weakened the national 
regulatory framework created over a decade by ANVISA 
and enabled a wider exposure of the medical class to the 
promotion of off-label drug use. 
Bevacizumab off-label indication: efficacy and 
safety critical evaluation
Regarding off-label indications, studies in animals 
have shown that bevacizumab has a longer half-life when 
compared to ranibizumab, which, on the other hand, has 
the following advantages: affinity 140 times higher than 
bevacizumab to its antigenic determinant; greater efficacy 
when diluted; lower immunogenicity.
In 2011 and 2012, two important comparative 
studies between bevacizumab and ranibizumab were 
published. These studies were conducted in 2011 by the 
CATT (Comparison of Age-Related Macular Degeneration 
Treatments Trial – United States) and IVAN (Inhibition 
of VEGF in Age-related Choroidal Revascularization – 
United Kingdom) studies.
Regarding the test protocol for the study performed 
by CATT, the patients treated with bevacizumab did not 
receive the fractioned drug, as in clinical practice (off-
label use). A 2-mL aliquot from an ampoule was used to 
prepare a single syringe, while the remaining content of 
said ampoule was discarded (Martin et al., 2012).
Regarding the protocol related to the assay performed 
by the IVAN study, the procedures about the fractioning 
used are not described. Thus, the study does not allow 
for efficacy and safety comparison between fractioned 
bevacizumab, as used in clinical practice, and ranibizumab 
in single-dose vials (Chakravarthy et al., 2012).
An additional issue regards the lack of studies to 
establish the indicated dose of bevacizumab for AMD 
treatment. In the United States, the most common 
dose of this drug is 1.25 mg/0.05 mL, whereas in other 
countries, the 2.50 mg/0.05 mL dose is frequently used. 
This recommendation was supported by the fact that the 
molar concentration after the intravitreal injection, using 
bevacizumab 1.50 mg, is similar to the one reached with a 
0.5 mg ranibizumab dose, as per a verbal communication 
from Professor Rosenfeld, University of Miami, Florida.
I n  t h e  s a m e  w a y,  n o  p h a r m a c o k i n e t i c s , 
pharmacodynamics, toxicology, and long-term safety 
(chronic use medication) studies were performed, as 
well as safety studies in elderly populations. Of note, 
these studies are essential for the approval and marketing 
of a new drug by the regulatory agencies by ANVISA, 
including in Brazil.
Regarding bevacizumab safety, the package insert 
reports VEGF systemic concentration reduction after 
intravitreal anti-VEGF therapy. Non-ocular systemic 
adverse events, including hemorrhages and arterial 
thrombotic events, have been reported after intravitreal 
injection; thus, there is a theoretical risk that these 
conditions may be related to systemic VEGF inhibition.
Furthermore, the IVAN study showed that the 
systemic VEGF median concentrations were significantly 
lower with bevacizumab use in comparison with 
ranibizumab (Chakravarthy et al., 2012). This result may 
impair neuronal cell survival, endothelial cell survival and 
proliferation, bone growth, and regeneration of fractures.
In the CATT study, the authors reported a higher 
quantity of serious systemic adverse events in patients 
treated with bevacizumab (24.4%). These results refer 
to the second year only, against 18% for ranibizumab. 
Considering the trend adjustments for the demographic 
characteristics and the concurrent diseases from the 
beginning of the groups, the risk of all severe systemic 
adverse events for bevacizumab is 30% higher when 
compared to the adverse events for ranibizumab (Martin 
et al., 2012).
F u r t h e r m o r e ,  a  h i g h e r  t r e n d  o f  v e n o u s 
thromboembolic events has been seen in treatments 
using Avastin® (1.7%) when compared to treatments using 
Lucentis® (0.5%). Gastrointestinal events have been seen 
with a higher frequency (hemorrhage, hernia, nausea, and 
vomiting) in patients treated with bevacizumab, 4.8% and 
1.8%, respectively, for bevacizumab and ranibizumab 
(p-value = 0.005) (Martin et al., 2012).
The Data and Safety Monitoring Committee of 
the IVAN clinical trial requested that the investigators 
perform new analyses of the safety results, joining the 
available data from the IVAN and CATT studies. This 
analysis was requested due to the statistic difference seen 
in the frequency of serious adverse events. The analysis 
confirmed a higher frequency of these events in patients 
treated with bevacizumab. The committee concluded that 
this result could not be seen as random.
Regarding long-term studies, ranibizumab has 
shown an adverse event rate similar to that of pivotal 
studies. This study enrolled patients under medication 
for a period of up to 7 years [Marina (Minimally Classic/
Occult Trial of the Anti-VEGF Antibody Ranibizumab 
in the treatment of Neovascular AMD) and ANCHOR 
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(Anti-VEGF Antibody for the Treatment of Predominantly 
Classic CNV in AMD)] (Brown et al., 2006; Rosenfeld et 
al., 2006).
The adverse events due to off-label use reported 
in the European package insert of the drug bevacizumab 
are: infectious endophthalmitis, intraocular inflammation 
(sterile uveitis, endophthalmitis, and vitritis), retinal 
detachment, retinal pigment epithelium tears, increased 
intraocular pressure, intraocular hemorrhage, such 
as vitreous hemorrhage or retinal hemorrhage, and 
conjunctival hemorrhage. On the other hand, the adverse 
events that are considered frequent for ranibizumab 
(affecting more than 1 out of 10 patients) and highlighted 
in its package insert are: eye inflammation, eye bleeding, 
visual disturbance, eye pain, small particles or stains 
in sight (vitreous floaters), blood stain in the eye, eye 
irritation, sensation of speck in the eye, increased tear 
production, eyelid margin inflammation or infection, dry 
eyes, eye redness or itchy eye, and increased intraocular 
pressure.
Considering that drug use shows a higher frequency 
among the elderly population, safety studies on this 
population have a major importance. Ranibizumab adverse 
events are known and did not show any increase in 
frequency in this age group, as reported on its package 
insert.
However, on the bevacizumab package insert, 
several warnings related to the type and frequency of 
serious adverse events are reported. Randomized clinical 
assays of bevacizumab (in the oncologic indication) with 
patients in the 65 years old or older age group showed 
increased risk of developing arterial thromboembolic 
events, including cerebrovascular accidents (CVA), 
transient ischemic attacks (TIA), and myocardial 
infarctions (MI). These diseases are exactly the ones 
which show a higher incidence in the elderly population. 
The additional adverse events reported on the package 
insert and associated with this drug are: grade 3 and 4 
leukopenia, thrombocytopenia, neutropenia, diarrhea, 
headache, nausea, and fatigue.
An additional issue related to bevacizumab safety 
regards its use in patients with renal failure (68% of 
patients with AMD have renal failure), diabetes, specially 
on the effect of wound healing, and hypertension. For the 
latter condition, a 34% increase was seen in its incidence 
after treatment with bevacizumab (Ranpura et al., 2012; 
Scartozzi et al., 2009). Lastly, the association of this 
drug to bisphosphonates (a drug distributed by SUS 
[Unified Health System]) for the treatment of osteoporosis 
may cause an increase in the incidence of mandible 
osteonechrosis.
Risks associated with fractioning multi-dose vials 
of parenteral drugs
Drugs with parenteral administration differ from 
other dosage forms, as they show unique requirements, 
due to the fact that they are injected directly into the body 
tissue through the main human body protection system, the 
skin (and mucous membranes). For this reason, these drugs 
should have the following characteristics: exceptional 
purity; lack of physical and chemical contaminants; and 
sterility (Avis, Levchuk, 2000).
With regard to parenteral drugs, it is essential 
that their primary package maintain its sterility until 
the time of use. In addition to this basic requirement, 
the packages used in the storage of sterile products 
should be compatible with the sterilization method, be 
durable, provide permanent sealing, avoid the entrance 
of contaminants and allow the withdrawal of its content 
without recontamination (Garfinkle, Henley, 2000).
Among packages for injectable drugs, multi-dose 
vials are the most popular, as they are more convenient and 
cost-effective (Motamedifar, Askarian, 2006). Nowadays, 
the term “multi-dose vial” is used in a confusing way by 
healthcare professionals. In daily practice, the term means 
any kind of vial that has been used more than once and that 
was stored for potential re-use. (Mattner,Gastmeier, 2004).
According to the Brazilian Pharmacopeia (2010), 
packages for multi-dose vials are airtight containers that 
allow the withdrawal of successive portions of its content, 
without modifying the strength, purity, and sterility of 
the remaining portion. The American Pharmacopeia also 
declares that multi-dose vials should contain preservative 
agents, except in cases in which the product’s components 
themselves have adequate antimicrobial properties, 
and that the volume should not exceed 30 mL. These 
specifications are required by the official compendia 
because, even with asepsis precautions (including 
sterile needles and syringes for dose withdrawal and 
closure surface disinfection), there is a significant risk of 
microbiological contamination in the package content.
Despite their advantages, multi-dose vials show 
high risks of microbiological contamination due to their 
repeated use. Related studies indicate that potentially 
pathogenic microorganisms may survive and, sometimes, 
proliferate in multi-dose vials, thus creating a potential 
risk for parenteral inoculation of pathogenic organisms 
(Nakashima et al.,1987; Dade et al., 2000).
The multi-dose vial contamination rate is estimated 
to be up to 27%; the consequences of said contaminations 
may be severe and may lead to nosocomial outbreaks of 
fungal, viral, and bacterial infections (Henry et al., 2001; 
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Kirschke et al., 2003; Mattner et al., 2004; Melnyk et al., 
1993; Moro et al., 1990).
Between 1985 and 2002,  mul t i -dose  v ia l 
contaminations and infections by HIV, by the hepatitis 
B and C viruses, by Plasmodium falciparum (Malaria), 
by Enterobacter cloacae, by Pseudomonas aeruginosa, 
among other pathogens, were reported in patients that 
used drugs and saline solutions from those vials (Mattner, 
Gastmeier, 2004).
Prevalence studies developed in Germany with the 
objective of assessing the multi-dose vial microbiological 
contamination showed that, out of 227 available vials in a 
certain hospital (1,300 beds), 2 (0.9%) were contaminated 
by Staphylococcus epidermidis, 114 (50%) were showing 
the opening date, 44 units (19%) were stored under 
refrigeration, and 109 (48%) of the drugs did not have 
preservatives in their formulation (Mattner, Gastmeier, 
2004).
A similar research conducted in Hospital Namzi, 
in Iran, showed that, out of 637 assessed vials, 36 
(5.6%) presented microbiological contamination, 
without any difference in the contamination between 
the different wards of the hospital or different types of 
medication. In this research, the most commonly identified 
microorganisms were part of the commensal microbiota, 
whereas Gram-positive bacteria (88.9%) were significantly 
more identified than Gram-negative ones (11.1%), with a 
higher frequency for Staphylococcus epidermidis (44.4%) 
and a lower frequency for Actinomyces viscosus (2.8%).
Aware of the risks inherent to the unsafe medical 
practice of dose fractioning, the American Pharmacopeia, 
in its 28th Edition, dated 2005, included chapter <797> 
Pharmaceutical Compounding–Sterile Preparations, 
which describes the basic requirements applied to health 
institutions, drugstores, medical facilities, and other 
facilities where pharmaceutical compounds and sterile 
preparations are manipulated, stored, and supplied. In 
this chapter, information on clean area specifications, 
environmental microbiological control, quality assurance 
programs, standard operational procedures, validations, 
periodical trainings, and aseptic manipulation assessment 
are required, in order to avoid unsafe practices, which 
cause a higher risk of disease for the patients.
Endophthalmitis and other risks related to 
bevacizumab multi-dose vial fractioning
Currently, injectable intravitreal administration of 
drugs has become widely used for the treatment of several 
retinal eye disorders. Intravitreal therapies are generally 
applied in medical clinics and in surgical environments, 
turning the risk of endophthalmitis into a major concern 
(Artunay et al., 2009).
Endophtha lmi t i s  i s  a  se r ious  in t raocula r 
inflammation, resulting from an eye cavity infection. 
Exogenous endophthalmitis occurs when infectious 
organisms develop in the eye due to their direct inoculation, 
by intraocular surgeries, traumas, or intravitreal injections 
(Lemley et al., 2007).
Several relevant issues about bevacizumab 
fractioning should be considered. Among them, the 
medication stability and sterility during the manipulation 
in the fractioning process should be assured, in order to 
avoid serious adverse events widely described in medical 
literature.
In recent investigations of infectious endophthalmitis 
outbreaks after intravitreal administration of the drug 
bevacizumab, a positive bacteria culture, including 
Streptococcus mitis/oralisit has been identified on 
the majority of patients and on the syringes used. The 
most probable cause appointed by researchers was 
contamination during syringe preparation, even with the 
use of aseptic techniques (Artunay et al., 2009; Goldberg 
et al., 2012).
In addition to the problems related to microbiological 
contamination, other researches that assessed the risks 
related to bevacizumab fractioning observed significant 
differences on the amount of bevacizumab between 
syringes resulting from fractioning, with an increase of 
up to 10 times in particulate material when compared to 
the original ampoule, and with contamination of silicone 
oil microparticles (Kahook et al., 2010; Liu et al., 2011).
In a document made available at ANVISA website, 
Roche discourages physicians from fractioning the product 
Avastin®, which contains the drug bevacizumab, due 
to the adverse events reported during marketing of this 
drug and identified in the pharmacovigilance monitoring. 
Furthermore, the manufacturer declares that the vial does 
not contain preservatives, thus, the product contamination 
is associated with fractioning.
As per the bevacizumab package insert, the 
medication does not contain any antimicrobial 
preservative; therefore, after opened, caution should be 
taken to ensure the sterility of the prepared solution. After 
mixing with saline solution for administration, the product 
should be used immediately and should only be stored in 
a refrigerator (2 - 8 ºC) for 24 hours.
Similarly, the Veteran Affairs, one of the United 
States departments that manages a wide chain of hospitals 
in the United States, has issued a report prohibiting the 
fractioned use of bevacizumab after reports of cases 
of serious eye events. The use of Avastin is currently 
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approved, but it is restricted to one ampoule per syringe, 
i.e., drug fractioning is not possible.
Clinical Protocol and Therapeutic Guidelines 
for AMD – Public Consultation No. 10, dated 
September 2012
On September 12, 2012, the Secretaria de Atenção à 
Saúde [Health Care Department] of the Ministry of Health 
released the Clinical Protocol and Therapeutic Guidelines 
– Age-Related Macular Degeneration (neovascular form) 
for public consultation (PUBLIC CONSULTATION No. 
10, DATED SEPTEMBER 12, 2012).
The protocol aims at establishing parameters about 
AMD in Brazil and national guidelines for diagnosis, 
treatment and follow-up of the subjects with this disease.
These guidelines incorporate ranibizumab as a 
therapeutic option; however, they consider the use of 
bevacizumab (off-label indication). Although the protocol 
claims that specialized literature shows low level results 
of therapeutic evidence, the inclusion of bevacizumab 
is justified as a safe alternative with a higher cost-
effectiveness when compared to ranibizumab.
CONCLUSION
This review work allowed the conclusion that the 
off-label indication of bevacizumab shows increased 
risks for patients when compared to the product with 
a specific therapeutic indication for AMD treatment, 
ranibizumab. These risks specially refer to the significant 
increase in adverse events. Furthermore, the risks related 
to multi-dose vials use for the patients were evidenced. 
These additional risks regard microbial contamination 
due to the multiple uses and reduced dose precision of the 
product. Therefore, the proposal of the Clinical Protocol 
and Therapeutic Guidelines for AMD treatment, as shown 
in Public Consultation No.10, dated September 12, 2012, 
may cause unnecessary risks for patients.
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